NXS.AX - Next Science Limited

ASX - ASX Delayed price. Currency in AUD

Next Science Limited

The Zenith Building, Tower A
Suite 1902 Level 19 821 Pacific Highway
Chatswood, NSW 2067
61 2 8607 5126

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees

Key executives

NameTitlePayExercisedYear born
Ms. Judith Mitchell M.B.A.MD, CEO & Exec. Director288.08kN/AN/A
Dr. Matthew Franco MynttiFounder & CTO366.61kN/AN/A
Ms. Jacqueline Butler CA (ICAEW)Chief Financial Officer267.91kN/AN/A
Mr. Jon SwansonChief Operating Officer265.18kN/AN/A
Mr. Martyn JacobsHead of Investor RelationsN/AN/AN/A
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICDCompany Sec.N/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the issues in human health caused by biofilms in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for postoperative wound; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Chatswood, Australia.

Corporate governance

Next Science Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.